Literature DB >> 132867

Comparative trial of influenza vaccines. II. Adverse reactions in children and adults.

D W Barry, R E Mayner, H D Hochstein, R C Dunlap, S C Rastogi, J E Hannah, R J Blackburn, J L Sullivan, R J Gerety.   

Abstract

Commercially prepared zonally and chromatographically purified bivalent (A/England-B/Mass) and monovalent (B/Hong Kong) inactivated influenza vaccines were given to 438 individuals 6-33 years old. The vaccines had been examined for antigen content by chick cell agglutination (CCA) tests and electron microscopic particle count determinations. Endotoxin and pyrogen content were determined by limulus amebocyte lysate (LAL) and rabbit pyrogenicity assays; and egg-associated protein contamination was estimated by total protein and single radial immunodiffusion assays. Although great differences (10-200-fold) were found in the amount of endotoxin or pyrogen in the vaccines, no significant differences were found in the febrile responses they induced. Both bivalent and monovalent vaccines induced fever of greater than or equal to 38 C at a rate of approximately 3 1/2-4% above background. The febrile responses were most frequent at 24 hours after inoculation and a higher rate was observed in children than adults. Local reactions consisting of tenderness, erythema or induration were seen in from 20-57% of the recipients and also were unrelated to the pyrogenic or host-derived materials in the vaccines. Adults had higher local reaction rates than children and some vaccines containing larger amounts of viral antigen induced significantly higher rates of reactivity than did vaccines containing smaller amounts of antigen. Although 37-51% of all recipients experienced either a local and/or febrile reaction to influenza immunization, the reactions were in general mild and would not consitute a significant disadvantage in the immunization of children over 6 years and adults to prevent influenza infection and its sequelae.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 132867     DOI: 10.1093/oxfordjournals.aje.a112273

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  10 in total

1.  Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project.

Authors:  Sharon K Greene; Martin Kulldorff; Edwin M Lewis; Rong Li; Ruihua Yin; Eric S Weintraub; Bruce H Fireman; Tracy A Lieu; James D Nordin; Jason M Glanz; Roger Baxter; Steven J Jacobsen; Karen R Broder; Grace M Lee
Journal:  Am J Epidemiol       Date:  2009-12-04       Impact factor: 4.897

2.  Subunit influenza vaccination in adults with asthma: effect on clinical state, airway reactivity, and antibody response.

Authors:  M K Albazzaz; J E Harvey; E A Grilli; E O Caul; A P Roome
Journal:  Br Med J (Clin Res Ed)       Date:  1987-05-09

3.  Influenza immunization of health care providers.

Authors:  N A Hynes
Journal:  J Gen Intern Med       Date:  1988 Jan-Feb       Impact factor: 5.128

4.  Reactogenicity and immunogenicity of a surface-antigen-adsorbed influenza virus vaccine in children.

Authors:  L M Eastwood; R Jennings; R D Milner; C W Potter
Journal:  J Clin Pathol       Date:  1979-06       Impact factor: 3.411

Review 5.  Influenza vaccination in the elderly.

Authors:  Jan Smetana; Roman Chlibek; Jana Shaw; Miroslav Splino; Roman Prymula
Journal:  Hum Vaccin Immunother       Date:  2017-08-04       Impact factor: 3.452

6.  Responses of volunteers to inactivated influenza virus vaccines.

Authors:  R Jennings; C W Potter; P M Massey; B I Duerden; J Martin; A M Bevan
Journal:  J Hyg (Lond)       Date:  1981-02

7.  Endotoxins in commercial vaccines.

Authors:  M R Geier; H Stanbro; C R Merril
Journal:  Appl Environ Microbiol       Date:  1978-09       Impact factor: 4.792

8.  Inactivated Whole Virus Particle Influenza Vaccine Induces Anti-Neuraminidase Antibodies That May Contribute to Cross-Protection against Heterologous Virus Infection.

Authors:  Chimuka Handabile; Toshiki Sekiya; Naoki Nomura; Marumi Ohno; Tomomi Kawakita; Masashi Shingai; Hiroshi Kida
Journal:  Vaccines (Basel)       Date:  2022-05-19

9.  Reduced reaction frequencies with repeated inactivated or live-attenuated influenza vaccination.

Authors:  Suzanne E Ohmit; Jonathan Gross; John C Victor; Arnold S Monto
Journal:  Vaccine       Date:  2008-12-16       Impact factor: 3.641

10.  Assessment of temporally-related acute respiratory illness following influenza vaccination.

Authors:  Sharon Rikin; Haomiao Jia; Celibell Y Vargas; Yaritza Castellanos de Belliard; Carrie Reed; Philip LaRussa; Elaine L Larson; Lisa Saiman; Melissa S Stockwell
Journal:  Vaccine       Date:  2018-03-07       Impact factor: 3.641

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.